Thrive Health and Wellness, LLC dba Thrive Health Solutions
Letter data
- Company
- Thrive Health and Wellness, LLC dba Thrive Health Solutions
- Recipient
- Doug Hatch | Owner | Thrive Health and Wellness, LLC dba Thrive Health Solutions | 88 Inverness Circle East, Ste A-204 | Englewood | , | CO | 80112-5521 | United States
- Issue date
- 2026-07-27
- Posted date
- Not available
- FDA office
- Center for Drug Evaluation and Research (CDER)
- Subject
- Not available
- Product
- Drugs
- CMS ID
- 714891
- Reference number
- Not available
- FEI
- Not available
- Inspection dates
- Not available
Normalized citations
21 CFR: None found
21 U.S.C.: None found
Related FDA links
No related FDA letter link is present in the source index.
Full source text
CLOSEOUT LETTER
Thrive Health and Wellness, LLC dba Thrive Health Solutions
MARCS-CMS 714891 —
July 27, 2026
More Warning Letters
Warning Letters
About Warning and Close-Out Letters
Delivery Method:
Via Electronic Mail - Delivery and Read Receipt Requested
Product:
Drugs
Recipient:
Recipient Name
Doug Hatch
Recipient Title
Owner
Thrive Health and Wellness, LLC dba Thrive Health Solutions
88 Inverness Circle East, Ste A-204
Englewood
,
CO
80112-5521
United States
Issuing Office:
Center for Drug Evaluation and Research (CDER)
United States
Secondary Issuing Offices
United States
Dear Mr. Hatch:
The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter #714891, issued on February 9, 2026. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.
You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
Matthew J. Lash
Acting Director
Office of Compounding Quality and Compliance
Office of Compliance
Center for Drug Evaluation and Research
Content current as of:
08/06/2026
Regulated Product(s)
Drugs